The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders
Open accessAbstract
BACKGROUND: Fatty acid amide hydrolase (FAAH) is an integral membrane enzyme that hydrolyzes the endocannabinoid anandamide and related amidated signaling lipids. Genetic or pharmacological inactivation of FAAH produces analgesic, anti-inflammatory, anxiolytic, and antidepressant phenotypes without showing the undesirable side effects of direct cannabinoid receptor agonists, indicating that FAAH may be a promising therapeutic target. OBJECTIVES: This review highlights advances in the development of FAAH inhibitors of different mechanistic classes and their in vivo efficacy. Also highlighted are advances in technology for the in vitro and in vivo selectivity assessment of FAAH inhibitors employing activity-based protein profiling (ABPP) and click chemistry-ABPP, respectively. Recent reports on structure-based drug design for human FAAH generated by protein engineering using interspecies active site conversion are also discussed. METHODS: The literature searches of Medline and SciFinder databases were used. CONCLUSIONS: There has been tremendous progress in our understanding in FAAH and development of FAAH inhibitors with in vivo efficacy, selectivity, and drug like pharmacokinetic properties.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125 · cited 5×
“The researchers isolated this hydrolase from rat liver membranes using affinity purification with a column covalently modified with an oleoyl trifluoromethyl ketone inhibitor derivative (see compound 5, Figure 4) [5].”
BackgroundMethodInfluentialSelf-citationThe Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077 · cited 2×
“Two endocannabinoids have been identified in mammals, N-arachidonoyl ethanolamine (anandamide; AEA) (1) and 2-arachidonoylglycerol (2-AG) (2) (Figure 1), and the biological actions of these signaling lipids are terminated by enzymatic hydrolysis [1-4].”
BackgroundThe molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957 · cited 1×
“Unlike hydrophilic neurotransmitters, whose action involves the uptake and storage of these small molecules into synaptic vesicles, AEA and other N-acyl ethanolamines (NAEs) are produced upon demand through activity-dependent cleavage of membrane lipid precursors [29,34].”
BackgroundModulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293 · cited 7×
“analgesia [11-15], anti-inflammation [16-18], anxiolysis [12,19,20] and antidepression [19,21] without disruptions in motility, cognition or body temperature [11,12,22,23].”
BackgroundResultInfluentialAn endocannabinoid mechanism for stress-induced analgesia
Hohmann, A. G., Suplita, R. L., Bolton, N. M., Neely, M. H., Fegley, D., Mangieri, R., Krey, J. F., Michael Walker, J., Holmes, P. V., Crystal, J. D., et al. (2005) · Nature · doi:10.1038/nature03658 · Cited by 778 · cited 1×
“) has also been found to enhance non-opioid, stress-induced analgesia, which was prevented by the CB1 antagonist rimonabant [121].”
BackgroundEndocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models
Kreitzer, A. C., & Malenka, R. C. (2007) · Nature · doi:10.1038/nature05506 · Cited by 735 · cited 2×
“Nonetheless, promising results have been obtained for FAAH inhibitors in preclinical models of acute, inflammatory, and neuropathic pain [14,15,18,22], as well as anxiety [12,19,20], depression [21,109], nausea [110], hypertension [111], pruritus [115], smoking cessation [112] and Parkinson’s disease [113] as detailed…”
BackgroundStructure and function of fatty acid amide hydrolase
McKinney, M. K., & Cravatt, B. F. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.082803.133450 · Cited by 680 · cited 2×
“The principle enzyme responsible for AEA degradation has been identified as the integral membrane protein FAAH [6].”
BackgroundSelf-citationChemical characterization of a family of brain lipids that induce sleep
Cravatt, B. F., Prospero-Garcia, O., Siuzdak, G., Gilula, N. B., Henriksen, S. J., Boger, D. L., & Lerner, R. A. (1995) · Science · doi:10.1126/science.7770779 · Cited by 620 · cited 1×
“Following the identification of the fatty acid primary amide oleamide as a sleep-inducing substance, an oleamide hydrolase activity was described [42] and suggested that it represents the same enzyme as the AEA/ NAE hydrolase [43].”
BackgroundSelf-citationGulyas, A. I., Cravatt, B. F., Bracey, M. H., Dinh, T. P., Piomelli, D., Boscia, F., & Freund, T. F. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03428.x · Cited by 561 · cited 1×
“, smooth endoplasmic reticulum, outer membrane of the mitochondria) in the somatodendritic compartment of neurons [46,47].”
BackgroundSelf-citationEnzymatic pathways that regulate endocannabinoid signaling in the nervous system
Ahn, K., McKinney, M. K., & Cravatt, B. F. (2008) · Chemical Reviews · doi:10.1021/cr0782067 · Cited by 529
Self-citation
Cited by
Strategies for Discovering and Derisking Covalent, Irreversible Enzyme Inhibitors
Johnson, D. S., Weerapana, E., & Cravatt, B. F. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.21 · Cited by 387
Self-citationHuggins, J. P., Smart, T. S., Langman, S., Taylor, L., & Young, T. (2012) · Pain · doi:10.1016/j.pain.2012.04.020 · Cited by 375
“This does not cause the overt untoward effects associated with exogenous compounds [3,6,11,16,27,32,33].”
BackgroundSavinainen, J. R., Saario, S. M., & Laitinen, J. T. (2012) · Acta Physiologica · doi:10.1111/j.1748-1716.2011.02280.x · Cited by 299
Ignatowska‐Jankowska, B. M., Ghosh, S., Crowe, M. S., Kinsey, S. G., Niphakis, M. J., Abdullah, R. A., Tao, Q., O' Neal, S. T., Walentiny, D. M., Wiley, J. L., et al. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12298 · Cited by 128
Self-citationGreco, R., Bandiera, T., Mangione, A., Demartini, C., Siani, F., Nappi, G., Sandrini, G., Guijarro, A., Armirotti, A., Piomelli, D., et al. (2015) · Cephalalgia · doi:10.1177/0333102414566862 · Cited by 63
“The antinociceptive effects of FAAH inhibitors positively correlated with increased central nervous system (CNS) endocannabinoid levels (25) and they might also share some of the adverse effects of cannabis.”
Background
Metadata
- Authors
- Ahn, K., Johnson, D. S., & Cravatt, B. F.
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa UK Limited
- Published
- 2009-06-09
- Volume
- 4
- Issue
- 7
- Pages
- 763-784
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W2161271648
- Cited by
- 194
- References
- 23
- FWCI
- 8.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders. https://app.cochat.ai/papers/10.1517/17460440903018857
- The paper
- Ahn, K., Johnson, D. S., & Cravatt, B. F. (2009). Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders. Expert Opinion on Drug Discovery. https://doi.org/10.1517/17460440903018857
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.